Sep 16, 2022
Ziolkowski previously served as CFO for BioAnalytix, as well as SiOnyx and VisEn Medical
American Canyon, Calif. - Sept. 16, 2022 – Cardiac Implants LLC, a leader in the development of minimally invasive annuloplasty technology, has hired John Ziolkowski, an experienced health care financial and operations executive, as Chief Financial Officer (CFO). Cardiac Implants is developing the world’s first transcatheter, complete ring annuloplasty technology, called Tri-Ring™, to address the serious problem of tricuspid valve regurgitation.
Ziolkowski brings more than 25 years of financial and operational management experience to his role at Cardiac Implants. Most recently, he served as CFO of BioAnalytix, a CRO providing analytical services to biotech and large pharma clients. Prior to BioAnalytix, Ziolkowski served as CFO for SiOnyx, an image sensor company, and VisEn Medical, a leading biomarker imaging company acquired by PerkinElmer in 2010. In these roles, he oversaw all aspects of finance, operations, IT, legal, compliance and human resource management. Ziolkowski holds a Bachelor of Arts in Economics/Accounting from the College of the Holy Cross and is a Certified Public Accountant (CPA).
“I am honored and excited to join Cardiac Implants at a time of significant opportunity for the Company. I look forward to working with Dr. Turco and the team on the Company’s mission to deliver its truly revolutionary Tri-Ring™ device to patients who suffer from structural heart disease,” Ziolkowski said.
Cardiac Implants CEO Dr. Mark A. Turco added, “I’m thrilled to have John join our team as we enter an important time in Cardiac Implants’ growth and development. John’s leadership and background from his prior roles as a CFO will help bring our finance operations to the next level and position the company for long-term success.”
ABOUT CARDIAC IMPLANTS, LLC
Cardiac Implants, LLC is engaged in the development and clinical investigation of percutaneous transcatheter devices for the treatment of structural heart diseases. The first product under development is a percutaneous complete ring annuloplasty device for the treatment of patients with tricuspid regurgitation. The Tri-Ring™ device is the only one of its kind designed to specifically meet the mechanical and functional endpoints of surgical ring annuloplasty, currently the clinical gold standard for surgical valve repair.
Founded in 2013, Cardiac Implants is headquartered in American Canyon, CA, with principal R&D and manufacturing operations in American Canyon and Yokneam, Israel. All products under development are investigational and for investigational use only and not approved for clinical use in any jurisdiction, including the United States.